The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potent therapeutic option for the management of obesity, demonstrating exceptional efficacy in several large-scale clinical trials. Despite their promising therapeutic outcomes, the rising popularity of these agents raises signi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Pharmacoepidemiology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2813-0618/3/4/25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103120882434048 |
|---|---|
| author | Sofía Echeverry-Guerrero Salomé González-Vélez Ana-Sofía Arévalo-Lara Juan-Camilo Calvache-Orozco Sebastián Kurt Villarroel-Hagemann Luis Carlos Rojas-Rodríguez Andrés M. Pérez-Acosta Carlos-Alberto Calderon-Ospina |
| author_facet | Sofía Echeverry-Guerrero Salomé González-Vélez Ana-Sofía Arévalo-Lara Juan-Camilo Calvache-Orozco Sebastián Kurt Villarroel-Hagemann Luis Carlos Rojas-Rodríguez Andrés M. Pérez-Acosta Carlos-Alberto Calderon-Ospina |
| author_sort | Sofía Echeverry-Guerrero |
| collection | DOAJ |
| description | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potent therapeutic option for the management of obesity, demonstrating exceptional efficacy in several large-scale clinical trials. Despite their promising therapeutic outcomes, the rising popularity of these agents raises significant concerns, particularly regarding their off-label use by individuals seeking weight loss for aesthetic reasons rather than addressing underlying metabolic health conditions. This article critically evaluates the efficacy and safety of GLP-1 RAs in obesity management. Additionally, it explores the economic implications and ethical challenges associated with the increasing demand for GLP-1 RAs. By addressing these dimensions, this article aims to facilitate informed and responsible decision-making in clinical practice, highlighting the need for individualized patient assessments and careful consideration of both short- and long-term safety risks. |
| format | Article |
| id | doaj-art-11b21117d2f548dbb52728ffa1b9ceb4 |
| institution | Kabale University |
| issn | 2813-0618 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacoepidemiology |
| spelling | doaj-art-11b21117d2f548dbb52728ffa1b9ceb42024-12-27T14:46:46ZengMDPI AGPharmacoepidemiology2813-06182024-11-013436537210.3390/pharma3040025The Inappropriate Use of GLP-1 Analogs: Reflections from PharmacoepidemiologySofía Echeverry-Guerrero0Salomé González-Vélez1Ana-Sofía Arévalo-Lara2Juan-Camilo Calvache-Orozco3Sebastián Kurt Villarroel-Hagemann4Luis Carlos Rojas-Rodríguez5Andrés M. Pérez-Acosta6Carlos-Alberto Calderon-Ospina7Pharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, ColombiaPharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, ColombiaCenter for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad Del Rosario, Bogota 111221, ColombiaCenter for Research in Genetics and Genomics (CIGGUR), Institute of Translational Medicine (IMT), School of Medicine and Health Sciences, Universidad Del Rosario, Bogota 111221, ColombiaPharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, ColombiaPharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, ColombiaObservatory of Self-Medication Behavior, School of Medicine and Health Sciences, Universidad Del Rosario, Bogota 111221, ColombiaPharmacology Unit, Department of Biomedical Sciences, School of Medicine and Health Sciences, Universidad del Rosario, Bogota 111221, ColombiaGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a potent therapeutic option for the management of obesity, demonstrating exceptional efficacy in several large-scale clinical trials. Despite their promising therapeutic outcomes, the rising popularity of these agents raises significant concerns, particularly regarding their off-label use by individuals seeking weight loss for aesthetic reasons rather than addressing underlying metabolic health conditions. This article critically evaluates the efficacy and safety of GLP-1 RAs in obesity management. Additionally, it explores the economic implications and ethical challenges associated with the increasing demand for GLP-1 RAs. By addressing these dimensions, this article aims to facilitate informed and responsible decision-making in clinical practice, highlighting the need for individualized patient assessments and careful consideration of both short- and long-term safety risks.https://www.mdpi.com/2813-0618/3/4/25glucagon-like peptide-1 receptor agonistssemaglutideexenatideliraglutidedulaglutidelixisenatide |
| spellingShingle | Sofía Echeverry-Guerrero Salomé González-Vélez Ana-Sofía Arévalo-Lara Juan-Camilo Calvache-Orozco Sebastián Kurt Villarroel-Hagemann Luis Carlos Rojas-Rodríguez Andrés M. Pérez-Acosta Carlos-Alberto Calderon-Ospina The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology Pharmacoepidemiology glucagon-like peptide-1 receptor agonists semaglutide exenatide liraglutide dulaglutide lixisenatide |
| title | The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology |
| title_full | The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology |
| title_fullStr | The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology |
| title_full_unstemmed | The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology |
| title_short | The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology |
| title_sort | inappropriate use of glp 1 analogs reflections from pharmacoepidemiology |
| topic | glucagon-like peptide-1 receptor agonists semaglutide exenatide liraglutide dulaglutide lixisenatide |
| url | https://www.mdpi.com/2813-0618/3/4/25 |
| work_keys_str_mv | AT sofiaecheverryguerrero theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT salomegonzalezvelez theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT anasofiaarevalolara theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT juancamilocalvacheorozco theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT sebastiankurtvillarroelhagemann theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT luiscarlosrojasrodriguez theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT andresmperezacosta theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT carlosalbertocalderonospina theinappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT sofiaecheverryguerrero inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT salomegonzalezvelez inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT anasofiaarevalolara inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT juancamilocalvacheorozco inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT sebastiankurtvillarroelhagemann inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT luiscarlosrojasrodriguez inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT andresmperezacosta inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology AT carlosalbertocalderonospina inappropriateuseofglp1analogsreflectionsfrompharmacoepidemiology |